Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study

BACKGROUND: Most conventional, oral, preventive treatments for migraine are non-specific and ~50% of patients discontinue them within six months. In 2018, the Food and Drug Administration approved three preventive migraine treatments: monoclonal antibodies (mAb) targeting the calcitonin gene-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnado, Oralee J, Manjelievskaia, Janna, Ye, Wenyu, Perry, Allison, Schuh, Kory, Wenzel, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976490/
https://www.ncbi.nlm.nih.gov/pubmed/35378732
http://dx.doi.org/10.2147/PPA.S346660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976490/
https://www.ncbi.nlm.nih.gov/pubmed/35378732
http://dx.doi.org/10.2147/PPA.S346660

Ejemplares similares